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Purpose: To retrospectively analyze the clinical characteristics of patients who were screened for mutations with the
ATP-binding cassette transporter gene ABCA4 (ABCA4) microarray in a routine clinical DNA diagnostics setting.
Methods: We performed a retrospective analysis of the medical charts of 65 patients who underwent an ABCA4 microarray
screening between the years 2002 and 2006. An additional denaturing gradient gel electrophoresis (DGGE) was performed
in these patients if less than two mutations were found with the microarray. We included all patients who were suspected
of autosomal recessive Stargardt disease (STGD1), autosomal recessive cone–rod dystrophy (arCRD), or autosomal
recessive retinitis pigmentosa at the time of microarray request. After a retrospective analysis of the clinical characteristics,
the patients who were suspected of STGD1 were categorized as having either a typical or atypical form of STGD1,
according to the age at onset, fundus appearance, fluorescein angiography, and electroretinography. The occurrence of
typical clinical features for STGD1 was compared between patients with different numbers of discovered mutations.
Results: Of the 44 patients who were suspected of STGD1, 26 patients (59%) had sufficient data available for a
classification in either typical (six patients; 23%) or atypical (20 patients; 77%) STGD1. In the suspected STGD1 group,
59% of all expected pathogenic alleles were found with the ABCA4 microarray. DGGE led to the finding of 12 more
mutations, resulting in an overall detection rate of 73%. Thirty-one percent of patients with two or three discovered
ABCA4 mutations met all typical STGD1 criteria. An age at onset younger than 25 years and a dark choroid on fluorescein
angiography were the most predictive clinical features to find ABCA4 mutations in patients suspected of STGD1. In 18
patients suspected of arCRD, microarray screening detected 22% of the possible pathogenic alleles.
Conclusions: In addition to confirmation of the diagnosis in typical STGD1, ABCA4 microarray screening is usually
requested in daily clinical practice to strengthen the diagnosis when the disease is atypical. This study supports the view
that the efficiency and accuracy of ABCA4 microarray screening are directly dependent upon the clinical features of the
patients who are screened.
The autosomal recessive form of Stargardt disease
(STGD1) is caused by variations in the ATP-binding cassette
transporter gene ABCA4 (ABCA4) [1]. The gene product of
ABCA4 is localized to the rim of the rod and cone outer
segment disc membranes [2,3]. Pathological mutations in
ABCA4 result in an accumulation of all-trans retinal in the
membrane of the photoreceptor disc. Following phagocytosis
of the photoreceptor outer segments, toxic derivatives of all-
trans retinal accumulate in the retinal pigment epithelium
(RPE) and may ultimately lead to RPE cell death and atrophy
of the overlying photoreceptor layer [4]. Besides STGD1,
ABCA4 mutations may also be found in a significant
percentage (65%) of patients with autosomal recessive cone–
rod dystrophy (arCRD) [5]. In addition, mutations in this gene
have been described in atypical autosomal recessive retinitis
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pigmentosa (arRP) and may play a role in age-related macular
degeneration [6,7].
STGD1 appears to be monogenic; no sibships have been
found in which ABCA4 alleles do not co-segregate with the
disease. However, intrafamilial variability of the phenotype
has been reported [8]. Differences between siblings may
indicate the influence of environmental factors as well as other
genes that modify the expression of a given ABCA4 genotype.
Moreover, ABCA4 has a large allelic diversity. The nucleotide
diversity of the ABCA4 coding region was found to be 9–400
times greater than that of two other macular disease genes that
were examined in a similar fashion (bestrophin 1 and EGF-
containing fibulin-like extracellular matrix protein 1) [9].
Allelic heterogeneity and the size of the gene have
substantially complicated genetic analysis of ABCA4-
associated retinal disease. All mutation detection techniques
that remain exclusively PCR-based are relatively inefficient,
expensive, and labor intensive. Therefore, the ABCA4
genotyping microarray was developed [10]. The ABCR400
microarray contains all disease-associated genetic variants
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and many polymorphisms of the ABCA4 gene that have been
reported in the peer-reviewed literature or that have been
directly reported to Asper Biotech, the producer of the
microarray. In 2003, Jaakson and coworkers [10] found a
mutation allelic detection rate of 55%–65% in patients with
STGD1 by using the microarray alone. In combination with a
conventional mutation detection method, for example, single-
strand conformation polymorphism (SSCP) technology, a
detection rate of about 70%–75% may be achieved.
This study evaluated the ABCA4 microarray in a routine
clinical DNA diagnostics setting by performing a
retrospective analysis of the clinical characteristics of patients
who were screened with the microarray.
METHODS
Sixty-five patients who underwent an ABCA4 microarray
screening between the years 2002 and 2006 at the Department
of Human Genetics, Radboud University Nijmegen Medical
Centre (Nijmegen, The Netherlands), were included in this
retrospective study. An ABCA4 microarray screening was
always requested by an ophthalmologist who saw the patient
at the outpatient department of our hospital. The most likely
clinical diagnosis, judged by the ophthalmologist, was noted
at the time of request. Information on family history, taking
into account hereditary eye diseases, was routinely obtained
before the genetic screening was requested. We included all
patients who were suspected of STGD1, arCRD, or arRP, so
no dominant inheritance pattern was seen in the families of
these patients. We had no influence on the decision making
of the clinicians who requested the microarray screening.
Only probands were included. Patients from families in which
we had already found ABCA4 mutations were excluded along
with patients whose clinical information was not available.
This study was approved by the local ethics committee and all
participants gave informed consent for using their data, in
accordance with the tenets of the Declaration of Helsinki.
Peripheral venous blood samples were obtained and the
genomic DNA was isolated from leukocytes for analysis
according to standard methods using salt extraction.
Microarray screening was performed by Asper Biotech
(Tartu, Estonia) according to a previously described method
[10]. If less than two mutations were found, an additional
denaturing gradient gel electrophoresis (DGGE) was
performed according to a previously described method, using
a gradient of 10% to 65% [11]. Primers were chosen to
surround all exons (primer sequences are available on
request). All mutations that were found by the chip or by
DGGE were confirmed by direct sequencing. The
pathogenicity of a certain mutation was determined by our
own research protocol based on the criteria described by
Cotton et al. [12]. Taken into account were for instance the
evolutionary conservation of an amino acid, the kind of
change (Grantham score), and information from the online
prediction programs SIFT and Polyphen. The occurrence of
novel variants was analyzed by sequence analysis in 100
control individuals from an earlier study [13]. Mutation
numbering throughout the text and tables is based on the
cDNA sequence (GenBank NM_000350). If available,
genetic information of family members was used for
segregation analysis. The effectiveness of the chip was
determined for each clinical indication by determining which
percentage of total expected pathogenic alleles was found.
We collected the age at onset, the best corrected visual
acuity (BCVA), fundus appearance according to Fishman’s
three-class system [14] (group I is characterized by disease
confined to the macula, group II by any flecks peripheral to
the temporal vascular arcades, whereas group III is
characterized by chorioretinal and/or RPE atrophy, and/or
bone spicules outside the macular area; Figure 1), fluorescein
angiography (FA), full-field electroretinography (ERG), and
electro-oculography (EOG) from the medical records. Full-
field ERG and EOG were performed according to the
International Society for Clinical Electrophysiology of Vision
(ISCEV) standards, except in eight patients who underwent
ERG examination before the ISCEV regulations, according to
a similar protocol [15]. When no ERG or EOG testing was
performed in our hospital, electrophysiologic findings were
collected from referring institutions (10 patients). The ERGs
were classified on the basis of the amplitudes of the scotopic
rod B wave, photopic B wave, and 30-Hz flicker. Amplitudes
of these different ERGs were considered to be abnormal when
their values were less than the mean 5% of our local standard
values. The resulting ERG recordings were classified in four
groups (normal ERG, reduced cone response, reduced rod
response, and reduced responses of both photoreceptor
populations).
Patients who were suspected  of   STGD 1  before  the
microarray screening were further subdivided into two
groups, the typical STGD1 group or the atypical STGD1
group. We considered four necessary clinical features of
typical STGD1 to be the following: 1) onset of symptoms
before the age of 25 years; 2) a fundus appearance of type I
or type II [14]; 3) a dark choroid on FA [16]; and 4) a normal
scotopic ERG. An age at onset before the age of 25 years was
chosen on the basis of a study that found a mean age at onset
of 15.8 years with a standard deviation of 9.6 years in 278
STGD1 families [17]. Darkness of choroid in FA was assigned
by an experienced retinal specialist (C.B.H.) without
knowledge of the other characteristics of the patient’s
phenotype. Patients without sufficient information on these
criteria for a particular analysis were excluded for that
analysis.
RESULTS
Sixty-five patients were included in this study, 31 males
(48%) and 34 females (52%). The mean age was 34.6 years
(standard deviation 15.7) at the time of the microarray
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screening, with a range from 4 to 69 years. In 44 patients
(67.7%) STGD1 was considered the most likely clinical
diagnosis before microarray screening. Of the remaining
patients, 18 patients (27.7%) were suspected to have arCRD,
and in three patients (4.6%) arRP was the most likely
diagnosis. Of the 44 patients with suspected STGD1, mutation
screening with the ABCA4 microarray allowed the
identification of 52 (59%) of a total of 88 expected pathogenic
alleles. DGGE led to the finding of 12 more mutations,
resulting in an overall detection rate of 73%.
The group of suspected STGD1 patients consisted of 12
patients (27%) in whom one mutation was found, 23 patients
(52%) in whom two mutations were found, and two patients
(5%) in whom three mutations were identified. In the group
of patients carrying two or more mutations, sufficient
information was available for segregation analysis in three
cases. In these cases, different mutations matched different
alleles. On retrospective analysis, two suspected STGD1
patients in whom mutations were identified could be classified
as arCRD. The diagnosis was not altered on the basis of the
genotype data but it was based on the clinical picture of these
patients. Of the remaining seven patients (16%) in whom no
mutations were found, the diagnosis of STGD1 was retained
in two patients after retrospective analysis of the clinical
picture.
In 18 patients (28%), arCRD was considered the most
likely clinical diagnosis before microarray screening. In these
patients, the microarray detected eight (22%) of 36 possible
pathogenic alleles. Four patients (22%) showed a
heterozygous sequence variant, and two patients (11%)
showed a compound heterozygous sequence variant. DGGE
analysis identified one additional homozygous mutation,
resulting in a detection rate of 28%. Retrospective analysis of
the clinical picture in patients without ABCA4 mutations did
not alter the diagnosis of arCRD. Finally, no mutations were
found in the three patients who had arRP as the most likely
diagnosis before microarray screening.
In 26 suspected STGD1 patients (59%), sufficient data
were available for a classification in either the typical or the
atypical STGD1 group. Six patients (23%) could be classified
into the typical and 20 patients (77%) into the atypical STGD1
group. The occurrence of the four defining features of typical
STGD1 is also separately presented in Table 1. All 74
mutations that were identified are listed in Table 2. Thirty-
three mutations (44.5%) were missense mutations. The group
of truncating mutations consisted of five nonsense mutations,
14 splice-site mutations, and five frameshift mutations,
corresponding with 6.75%, 19%, and 6.75% of the total,
respectively. The 2588G>C mutation was found in 11% and
may result in a deletion or an amino acid substitution [13].
Finally, the 5461–10T>C mutation was found in 12%. The
precise mechanism of the pathogenicity of this mutation has
not been elucidated [18]. Webster and coworkers found that
this mutation was significantly enriched in an STGD1 cohort
when it was compared with a non-STGD1 cohort [9]. Some
authors proposed the likelihood of a linkage disequilibrium of
5461–10T>C with an unidentified pathologic ABCA4
mutation [19].
Fourteen different mutations were found that, to the best
of our knowledge, have not been reported before (Table 2).
Ten of them are mutations which were not included in the
microarray at the time of analysis. They were found with
DGGE analysis and were judged to be pathogenic according
to our research protocol. First, the 6411T>A mutation, is
predicted to result in a premature stop codon at amino acid
number 2137. Second, there are two new mutations that affect
the splicing of the RNA. Both 303+4A>C and 4352+1G>A
are located in the consensus sequence of the intronic splice
donor site. Therefore, these mutations are likely to be
pathogenic. This is also the case with the 5762_5763 dup
mutation as it results in a frameshift mutation and therefore
disturbs the reading frame in the mRNA. Finally, DGGE
found six new missense mutations. These mutations give rise
to a new amino acid with different polarity or charge, except
for the 2906A>G mutation, which results in a substitution of
Figure 1. Fundus appearances according to Fishman’s three-class system [14]. A: This photograph represents fundus appearance type I, which
is characterized by a small atrophic-appearing foveal lesion. This lesion can be surrounded by parafoveal or perifoveal yellowish white lesions.
B: This photograph represents fundus appearance type II, showing numerous yellowish white fundus lesions extending beyond the vascular
arcades. C: This photograph represents fundus appearance type III, which is characterized by extensive atrophic-appearing changes of the
retinal pigment epithelium throughout the posterior pole, extending beyond the vascular arcades.
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a lysine to an arginine. These amino acids have a net positive
charge located at the amino group. An explanation for the
pathogenicity of this mutation may be that this amino acid is
located in a highly conserved region of the ABCR protein.
In two cases, DGGE analysis in our laboratory revealed
a mutation that was also included in the microarray, whereas
microarray results were normal for screening of this mutation.
DISCUSSION
For an evaluation of the ABCA4 microarray in daily clinical
practice, it is useful to look at the consequences of the
screening results. The classification of patients suspected of
STGD1 into a typical and an atypical STGD1 group
(according to our definition) revealed that only 31% of
patients with two or three discovered ABCA4 mutations met
all  typical criteria of Stargardt disease (Table 1). On the other
hand, in four out of six patients in the typical STGD1 group
(67%), two or more ABCA4 mutations were found. A
limitation of this observation is that only 26 patients (59%) of
all patients suspected of STGD1 underwent all examinations
that were required to classify patients in the typical or atypical
STGD1 group. When looking separately at the different
defining features of typical STGD1 in Table 1, we conclude
that only an age at onset before 25 years and a dark choroid
on FA are more prevalent in patients with more discovered
mutations than in patients with less or no discovered mutations
in the ABCA4 gene. The most striking is the difference in age
at onset, which was younger than 25 years in 80% of patients
with two or three discovered ABCA4 mutations, in 67% of
patients with one discovered mutation, and in only 29% of
patients where no mutations were found. Furthermore, a dark
choroid on FA was present in 81% of patients with two or
three discovered ABCA4 mutations, in 40% of patients with
one discovered mutation, and in 43% of patients where no
mutations were found. The latter rates differ from an earlier
study where a dark choroid was found in only two of 12
patients (17%) with two discovered mutations and five of 17
patients (29%) with one discovered mutation [14]. This may
be due to the lower number of patients in that study as well as
a difference in clinical judgment of the FA.
Two suspected STGD1 patients in whom mutations were
identified could retrospectively be classified as arCRD
patients. These patients received additional examinations
(e.g., full-field ERG) and routine follow-up as standard
medical care. As a result, the diagnosis could change to
arCRD, for instance as the disease progressed to a more
panretinal dysfunction [20]. No mutations were found in
seven of the 44 patients with suspected STGD1. The diagnosis
was changed on retrospective analysis of the clinical
characteristics in two of these cases. In one case, the diagnosis
had changed to multifocal pattern dystrophy simulating
STGD1/fundus flavimaculatus, after a mutation was detected
in the peripherin/RDS gene. This patient was also described
as C-III:2 in a study by Boon and colleagues [21]. In the other
case, the absence of ABCA4 mutations led to the retrospective
diagnosis of central areolar choroidal dystrophy. The
diagnosis of three other patients was still uncertain after the
microarray screening because the clinical picture together
with the negative results of the screening were too atypical for
a certain diagnosis. In the remaining two patients in whom the
diagnosis STGD1 was retained, one had a different clinical
picture. Typical macular lesions were found accidentally, and
the patient did not experience visual loss at the age of 42.
However, she had a dark choroid and a normal ERG. This may
be a form of asymptomatic late-onset STGD1 [20].
In our routine clinical DNA diagnostics setting, we
obtained an ABCA4 mutation detection rate of 59% with the
microarray only and 73% with additional DGGE analysis in
patients who were suspected of STGD1. These detection rates
correspond with the detection rates found by other studies
[10,22]. In the study of Maia-Lopez and coworkers, a
detection rate of 55% that was obtained with the microarray
alone was elevated to 67% with additional denaturing high-
performance liquid chromatography (dHPLC) [22]. In
TABLE 1. OCCURRENCE OF DIFFERENT TYPICAL CLINICAL FEATURES OF STARGARDT DISEASE IN PATIENTS STRATIFIED BY THE NUMBER OF DISCOVERED ABCA4
MUTATIONS.
Clinical features 0 mutations 1 mutation 2–3 mutations Total of patients1
Number of patients 7 12 25 44
Age at onset <25 years 2/7 (29%) 8/12 (67%) 20/25 (80%) 44
Fundus appearance I or II2 5/7 (71%) 9/12 (75%) 20/25 (80%) 44
Dark choroid at FA 3/7 (43%) 4/10 (40%) 17/21 (81%) 38
Normal scotopic ERG 5/6 (83%) 7/7 (100%) 14/16 (88%) 29
Typical Stargardt3 1/6 (17%) 1/7 (14%) 4/13 (31%) 26
This table shows the proportion of patients suspected of Stargardt disease with typical clinical features of this disease. Results
are separately shown for the patients with no, one, and more than one discovered ABCA4 mutations. Abbreviations in the table
are: ABCA4, ATP-binding cassette transporter gene ABCA4 ; FA, fluorescein angiography; ERG, full-field electroretinography.
Superscript one indicates that patients from whom sufficient information was available were included in the analysis; superscript
two indicates according to Fishman’s three-class system [14]; superscript three indicates typical Stargardt disease according to
the occurrence of the four above mentioned clinical features.
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TABLE 2. DISCOVERED MUTATIONS IN THE ABCA4 GENE IN THE PATIENTS INCLUDED IN THIS STUDY
Nucleotide change Effect Alleles References
Mutations already included in the ABCA4 microarray
c.286A>G p.Asn96Asp 2 [25]
c.656G>C p.Arg219Thr 1 [10]
c.740A>T p.Asn247Ile 1 This study*
c.768G>T splice site 7 [13]
c.899C>A p.Thr300Asn 1 [14]
c.1805G>A p.Arg602Gln 1 [9]
c.1822T>A p.Phe608Ile 2 [13]
c.1853G>A p.Gly618Glu 1 [19]
c.1938–1G>A splice site 1 [26]
c.2588G>C p.DelGly863/Gly863Ala 8 [13]
c.2919del exons20–22 deletion/frameshift 2 [13]
c.3335C>A p.Thr1112Asn 1 [13]
c.3874C>T p.Gln1292X 1 This study*
c.3899G>A p.Arg1300Gln 1 [27]
c.4297G>A p.Val1433Ile 1 [17]
c.4462T>C p.Cys1488Arg 1 [17]
c.4506C>A p.Cys1502X 1 This study*
c.4539+1G>T splice site 1 [28]
c.4774+1G>A splice site 1 [1]
c.5161–5162delAC p.Thr1721fs 1 [27]
c.5337C>A p.Tyr1779X 1 This study*
c.5461–10T>C unknown 9 [9]
c.5537T>C p.Ile1846Thr 1 [13]
c.5693G>A p.Arg1898His 1 [1]
c.5715+5G>A splice site 2 [28]
c.5882G>A p.Gly1961Glu 10 [1]
c.6088C>T p.Arg2030X 1 [14]
c.6089G>A p.Arg2030Gln 1 [9]
c.6238–6239delTC p.Ser2080fs 1 [29]
c.6529G>A p.Asp2177Asn 1 [1]
New mutations found with DGGE analysis
c.303+4A>C splice site 1
c.872C>T p.Pro291Leu 1
c.2906A>G p.Lys969Arg 1
c.2947A>G p.Thr983Ala 1
c.3233G>A p.Gly1078Glu 1
c.3305A>T p.Asp1102Val 1
c.4353+1G>A splice site 1
c.5113C>T p.Arg1705Trp 1
c.5762_5763dup p.Ala1922fs 1
c.6411T>A p.Cys2137X 1
Total 74
Mutations are designated by their nucleotide change, followed by their effect on the protein and the number of alleles that were
found with the mutation. References are shown for mutations that have been earlier reported. Abbreviations in the table are:
ABCA4, ATP-binding cassette transporter gene ABCA4; DGGE, denaturing gradient gel electrophoresis. The asterisks indicate
the mutations that were included in the microarray, but to our knowledge, have not been reported before.
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arCRD, we have found a detection rate of 22% with the
microarray alone; the detection rate was 28% with additional
DGGE. In RP patients, we found no mutations. Compared
with an earlier study, which found a detection rate of 33% in
arCRD and 5.6% in arRP with the microarray only, our
detection rates are low [19]. However, in another study at least
one mutation was found using dHPLC in 23.6% of the patients
with arCRD or sporadic CRD. No significant difference was
found between the arCRD cases and the sporadic CRD cases.
When the detection rate is calculated in the same way as in
our study, a mutation was discovered in 19 of the 110 alleles
(17%) [23]. Overall, we can not draw strong conclusions from
our data regarding arCRD and arRP because mutations were
screened in only 18 arCRD patients and three arRP patients.
In our study, microarray screening missed two mutations
that had already been tested by the microarray, leading to 3%
false-negative results. A possible explanation may be that the
signals of the microarray for these mutations were too weak.
False-positive results were not found in this study by direct
sequencing. In a recent study by Aguirre-Lamban and
coworkers, STGD1, arCRD, and arRP patients in whom the
ABCA4 microarray identified none or only one allele, were
further evaluated by dHPLC and multiplex ligation-dependent
probe amplification (MLPA). Both false-negative and false-
positive rates for the microarray were 1.6%. A mutation
detection rate of 43.5% for the microarray was increased to
64.5% by dHPLC alone [24]. We no longer use DGGE to
search for unrevealed mutations. Instead, we use direct
sequencing, which is now the gold standard.
The total carrier frequency of mild, moderate, or severe
ABCA4 mutations has been estimated to be one in 17 [13].
Therefore, we cannot exclude that patients in whom we have
found only one mutation are coincident carriers of an
ABCA4 mutation (i.e., that this mutation is not involved in the
disease of a patient). However, the mutations in the patients
in this study may be assumed to be involved in the disease
based on the clinical pictures of these patients. In addition, we
have also determined the pathogenicity of all discovered
variants according to the criteria of Cotton and coworkers
[12].
In the last decade, it has become feasible for the general
ophthalmologist to obtain molecular genetic support for a
clinical diagnosis, for instance of STGD1. In daily clinical
practice, in addition to confirmation of the diagnosis in typical
STGD1, ABCA4 microarray screening is usually requested to
strengthen the diagnosis when the disease is atypical. Most
STGD1 patients in our study, even those in whom two
ABCA4 mutations were found, did not meet all typical disease
criteria. In addition, our study supports the view that the
efficiency and accuracy of the ABCA4 microarray are directly
dependent upon the clinical features of the patients who are
screened. DGGE analysis can raise the detection rate from
59% to 73% in patients who are suspected of STGD1 disease
and may find mutations that are undetected by the microarray.
When no mutations are found, this does not entirely exclude
the diagnosis of STGD1 but may lead to a change in diagnosis
on later follow-up.
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